Industry Newsroom

Viva Biotech to Acquire 80% Stake in Chinese CDMO Platform Langhua for USD368m, Ninhua Group, Nuobai Investments, and Zhining Investments Exit

Hong Kong-listed Viva Biotech has agreed to acquire an 80% stake in China-based contract development manufacturing organization (CDMO) company Zhejiang Langhua Pharmaceutical for USD368m. The transaction, which is pending approval, will facilitate an exit for existing shareholders including Ninhua Group, Nuobai Investments, and Zhining Investments. Read more